Trial Profile
A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- 10 Jun 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014, as per ClinicalTrials.gov record.
- 01 Apr 2014 Planned End Date changed from 1 Jul 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
- 31 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.